Serina Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SER research report →
Price Chart
About the company
Serina Therapeutics, Inc. , a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease.
- CEO
- Steven A. Ledger
- IPO
- 2018
- Employees
- 16
- HQ
- Huntsville, AL, US
Get TickerSpark's AI analysis on SER
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $30.14M
- P/E
- -1.07
- PEG
- 0.02
- P/S
- 0.00
- P/B
- 1.76
- EV/EBITDA
- -0.47
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -222.42%
- ROIC
- -116.37%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-24,022,000
- Net Income
- $-19,182,000-72.2%
- EPS
- $-1.91-26.5%
- OCF Growth
- -4.8%
- FCF Growth
- -4.6%
- 52W High
- $5.71
- 52W Low
- $1.22
- 50D MA
- $2.38
- 200D MA
- $2.14
- Beta
- 0.03
- RSI (14)
- 40
- Avg Volume
- 64.02K
No earnings-call transcripts are available for SER yet.
- Free Float
- 13.3%
- Shares Outstanding
- 15.00M
- Float Shares
- 1.99M
of shares held by institutions
25 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Sio Capital Management, LLC | 1.00M | 0 |
| Vanguard Group Inc | 180.01K | 0 |
| Vanguard Capital Management LLC | 162.20K | ▲ 3.06K |
| Waverly Advisors, LLC | 67.49K | 0 |
| Geode Capital Management, LLC | 51.01K | ▼ 13.97K |
| Keel Point, LLC | 21.51K | 0 |
| Northern Trust Corp | 20.77K | ▲ 20.77K |
| Vanguard Fiduciary Trust Co | 20.01K | 0 |
| Avidian Wealth Solutions, LLC | 18.80K | 0 |
| Jane Street Group, LLC | 15.44K | ▼ 24.21K |
| State Street Corp | 12.76K | 0 |
| Caitong International Asset Management Co., Ltd | 3.74K | ▼ 238 |
Held by 21 ETFs
Biggest fund positions in SER by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 22, 26 | Simon Farrell | other | 30,500 |
| Jul 22, 26 | Simon Farrell | other | 0 |
| Jul 7, 26 | Brannan Stephen K. | buy | 1,000 |
| Jun 17, 26 | Venkatesan Jay | other | 224,152 |
| Jun 17, 26 | Venkatesan Jay | other | 15,250 |
| May 22, 26 | Venkatesan Jay | buy | 589 |
| Jun 17, 26 | Venkatesan Jay | other | 96,525 |
| Jun 17, 26 | Bailey Gregory | other | 6,666,667 |
| Jun 17, 26 | Bailey Gregory | other | 3,333,333 |
| Jun 17, 26 | Bailey Gregory | other | 1,770,805 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SER coverage
Recent articles, reports, and earnings notes.
No research on SER yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SER report →Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress"
globenewswire.com · Sep 23
Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Sees Significant Decline in Short Interest
defenseworld.net · Sep 14
Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Sep 10
Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2
globenewswire.com · Sep 9
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com · Aug 13
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
globenewswire.com · Jul 24
Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson's Disease
globenewswire.com · Jul 23
Serina Therapeutics Appoints Farrell Simon to its Board of Directors
globenewswire.com · Jul 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.